

# Riccardo M Ragona

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5089194/riccardo-m-ragona-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

1,789  
citations

23  
h-index

41  
g-index

57  
ext. papers

2,025  
ext. citations

3.8  
avg, IF

3.93  
L-index

#	Paper	IF	Citations
57	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. <i>Tumori</i> , <b>2021</b> , 107, 182-187	1.7	1
56	Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 138, 52-58	5.3	21
55	Small field correction factors determination for several active detectors using a Monte Carlo method in the Elekta Axesse linac equipped with circular cones. <i>Physics in Medicine and Biology</i> , <b>2019</b> , 64, 11NT01	3.8	5
54	Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 481-486	5.3	18
53	Evaluation of dose recalculation vs dose deformation in a commercial platform for deformable image registration with a computational phantom. <i>Medical Dosimetry</i> , <b>2018</b> , 43, 82-90	1.3	6
52	Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients. <i>Medical Oncology</i> , <b>2018</b> , 35, 150	3.7	7
51	Variability of clinical target volume delineation for rectal cancer patients planned for neoadjuvant radiotherapy with the aid of the platform Anatom-e. <i>Clinical and Translational Radiation Oncology</i> , <b>2018</b> , 11, 33-39	4.6	11
50	Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation. <i>Cancer Investigation</i> , <b>2018</b> , 36, 279-288	2.1	4
49	Hematologic toxicity in anal cancer patients during combined chemo-radiation: a radiation oncologist perspective. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 335-345	3.5	13
48	Incorporating FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation. <i>BMC Cancer</i> , <b>2017</b> , 17, 710	4.8	17
47	No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer. <i>British Journal of Radiology</i> , <b>2017</b> , 90, 20170143	3.4	6
46	Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3cm. <i>Medical Oncology</i> , <b>2016</b> , 33, 104	3.7	4
45	Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. <i>Medical Oncology</i> , <b>2016</b> , 33, 72	3.7	23
44	Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. <i>British Journal of Radiology</i> , <b>2016</b> , 89, 20150832	3.4	31
43	Evaluation of various approaches for assessing dose indicators and patient organ doses resulting from radiotherapy cone-beam CT. <i>Medical Physics</i> , <b>2016</b> , 43, 2515	4.4	5
42	Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. <i>Physica Medica</i> , <b>2016</b> , 32, 600-6	2.7	43
41	Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. <i>Anticancer Research</i> , <b>2016</b> , 36, 1943-8	2.3	13

40	Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. <i>Anticancer Research</i> , <b>2016</b> , 36, 2027-32	2.3	15
39	Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 161-8	4	42
38	Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 524-9	4	51
37	Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes. <i>Anticancer Research</i> , <b>2015</b> , 35, 6247-54	2.3	8
36	Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 370-5	4	39
35	Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. <i>Technology in Cancer Research and Treatment</i> , <b>2014</b> , 13, 37-45	2.7	33
34	Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. <i>World Journal of Urology</i> , <b>2013</b> , 31, 411-5	4	10
33	Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 1141-7	4.9	2
32	Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 311-6	4	33
31	Postoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysis. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 194-9	4.9	15
30	Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. <i>Practical Radiation Oncology</i> , <b>2013</b> , 3, 216-222	2.8	15
29	May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 1955-60	4.9	8
28	Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment. <i>Urologia Internationalis</i> , <b>2013</b> , 90, 288-93	1.9	8
27	Comparison of Gafchromic EBT2 and EBT3 for patient-specific quality assurance: cranial stereotactic radiosurgery using volumetric modulated arc therapy with multiple noncoplanar arcs. <i>Medical Physics</i> , <b>2013</b> , 40, 082105	4.4	22
26	125I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience. <i>Tumori</i> , <b>2013</b> , 99, 83-87	8.7	8
25	Stereotactic body radiation therapy for lung metastases. <i>Lung Cancer</i> , <b>2012</b> , 75, 77-81	5.9	107
24	Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin Lymphoma: dosimetric comparison and clinical considerations. <i>Radiation Oncology</i> , <b>2012</b> , 7, 186	4.2	72
23	Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase activity in pressure overload-induced cardiac failure. <i>Circulation</i> , <b>2011</b> , 123, 391-9	16.7	52

22	Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. <i>Lung Cancer</i> , <b>2010</b> , 68, 72-7	5.9	218
21	Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 2851-9	1.1	24
20	Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. <i>Acta Oncologica</i> , <b>2009</b> , 48, 571-7	3.2	50
19	Late toxicity in children undergoing hematopoietic stem cell transplantation with TBI-containing conditioning regimens for hematological malignancies. <i>Strahlentherapie Und Onkologie</i> , <b>2009</b> , 185 Suppl 2, 17-20	4.3	26
18	Absolute and relative dose measurements with Gafchromic EBT film for high energy electron beams with different doses per pulse. <i>Medical Physics</i> , <b>2008</b> , 35, 5463-70	4.4	12
17	Stereotactic body radiation therapy for early non-small cell lung cancer: experience at the University of Turin. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S47	8.9	8
16	Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. <i>International Journal of Dermatology</i> , <b>2007</b> , 46, 864-7	1.7	7
15	Preoperative endoscopic sphincterotomy versus laparoendoscopic rendezvous in patients with gallbladder and bile duct stones. <i>Annals of Surgery</i> , <b>2006</b> , 244, 889-93; discussion 893-6	7.8	112
14	Clinical use of EBT model Gafchromic film in radiotherapy. <i>Medical Physics</i> , <b>2006</b> , 33, 4314-9	4.4	141
13	Impaired elimination of DNA double-strand break-containing lymphocytes in ataxia telangiectasia and Nijmegen breakage syndrome. <i>DNA Repair</i> , <b>2006</b> , 5, 904-13	4.3	40
12	Radiotherapy after surgery for advanced adenoid cystic carcinoma of paranasal sinus. <i>Lancet Oncology</i> , <b>2005</b> , 6, 994-6	21.7	4
11	Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. <i>Cancer</i> , <b>2002</b> , 95, 90-7	6.4	56
10	Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. <i>Cancer</i> , <b>2001</b> , 91, 541-7	6.4	122
9	Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. <i>Head and Neck</i> , <b>2001</b> , 23, 298-304	4.2	6
8	Surgery or Radiotherapy for Early Stages Carcinomas of the Glottic Larynx. <i>Tumori</i> , <b>1999</b> , 85, 188-193	1.7	
7	Treatment of malignant neoplasms of the parotid gland. <i>Otolaryngology - Head and Neck Surgery</i> , <b>1999</b> , 121, 627-32	5.5	77
6	Results of hypofractionated stereotactic re-irradiation on 13 locally recurrent nasopharyngeal carcinomas. <i>Radiotherapy and Oncology</i> , <b>1999</b> , 53, 23-8	5.3	28
5	Prognostic Factors of Cervical Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. <i>Tumori</i> , <b>1997</b> , 83, 922-926	1.7	23

4	Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. <i>Journal of Immunotherapy</i> , <b>1996</b> , 19, 125-33	5	27
3	Microvessel count is predictive of patientsTsurvival in laryngeal squamous-cell carcinoma. <i>International Journal of Cancer</i> , <b>1996</b> , 69, 426-7	7.5	3
2	Results of chemotherapy plus external reirradiation in the treatment of locally advanced recurrences of nasopharyngeal carcinoma. <i>European Journal of Cancer Part B, Oral Oncology</i> , <b>1992</b> , 28B, 109-11		12
1	Hyperthermia alone in the treatment of recurrences of malignant tumors. Experience with 60 lesions. <i>Cancer</i> , <b>1990</b> , 66, 2191-5	6.4	25